Lenacapavir NEW
| Price | $333 | $690 | $1130 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-05-09 |
Product Details
| Product Name: Lenacapavir | CAS No.: 2189684-44-2 |
| Purity: 99.61% | Supply Ability: 10g |
| Release date: 2025/05/09 |
Product Introduction
Bioactivity
| Name | Lenacapavir |
| Description | Lenacapavir (GS-6207) is the first HIV-1 capsid inhibitor approved by the U.S. Food and Drug Administration, the European Medicines Agency, and Health Canada for the treatment of MDR HIV-1 infection.[3] |
| In vitro | The half-maximal effective concentration (EC50) of lenacapavir in MT-4 cells is 105 pmol/L; the half-maximal effective concentration (EC50) in primary human CD4 cells is 32 pmol/L; and the half-maximal effective concentration (EC50) in macrophages is 56 pmol/L. [1] |
| In vivo | The pharmacokinetics of lenacapavir after a single oral dose are nonlinear and dose-proportional over the dose range of 50-1800 mg, whereas they are dose-proportional when administered subcutaneously at 309-927 mg. The median half-life after oral and subcutaneous administration is 10 to 12 days and 8 to 12 weeks, respectively. The bioavailability of oral lenacapavir is 6-10%, with peak concentrations measured after 4 hours. Subcutaneous lenacapavir is completely absorbed and slowly released from the injection site, with peak plasma concentrations reached 84 days after administration. After a single subcutaneous dose of 900 mg, plasma concentrations remain well above the response threshold for more than 6 months, but oral lenacapavir is used for the initial loading phase because of slow initial diffusion into the circulation. The volume of distribution of lenacapavir is 976 L, and the drug is 99.8% protein bound, as calculated from a population PK study. [2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 195 mg/mL (201.39 mM), Sonication is recommended. |
| Keywords | PBMCs | MT-4 | Lenacapavir | Inhibitor | inhibit | Human immunodeficiency virus | HIVProtease | HIV-1 | HIV Protease | HIV | GS6207 | GS 6207 | capsid | antiretroviral |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Emtricitabine | Kaempferol | Dolutegravir intermediate-1 | Dextran sulfate sodium salt (MW 4500-5500) | Dimethyl fumarate | Lamivudine | Chloroquine phosphate | Valproic Acid | Decanedioic acid | Tenofovir |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Approved Drug Library | EMA Approved Drug Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Clinical Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Infection Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $333.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-05-09 | |
| $0.00/1mg |
VIP6Y
|
Jinan Jianfeng Chemical Co., Ltd
|
2025-01-09 | |
| $0.00/1mg |
VIP6Y
|
Jinan Jianfeng Chemical Co., Ltd
|
2025-01-09 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY